SCHEMBL12424633

SCHEMBL12424633

COc1cc2c(O)cc3c(c2cc1OC)-c1ccccc1-c1ccccc1C31c2ccccc2-c2ccccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.40
ESR2 Q92731 1/20 0.40
EP300 Q09472 1/20 0.39
PDK2 Q15119 4/20 0.37
PARP1 P09874 2/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
TP53 P04637 1/20 0.36
TSHR P16473 1/20 0.36
GAA P10253 3/20 0.36
HPGD P15428 1/20 0.36
KMT2A Q03164 5/20 0.34
MEN1 O00255 4/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
NQO2 P16083 1/20 0.33
CYP1A1 P04798 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP1B1 Q16678 1/20 0.33
NPC1 O15118 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL165110 0.83 PDK2 (0.40) EP300PDK2PARP1CA1CA2
SCHEMBL30125362 0.83 PDK2 (0.40) EP300PDK2PARP1CA1CA2
SCHEMBL12424610 0.82 EHMT2 (0.35) EP300PDK2PARP1GAAHPGD
SCHEMBL12424702 0.82 PARP1 (0.35) EP300PDK2PARP1CA1CA2
SCHEMBL12424645 0.82 PARP1 (0.35) ESR1ESR2EP300PDK2PARP1
SCHEMBL21111101 0.82 PDK2 (0.42) EP300PDK2PARP1CA1CA2
SCHEMBL26629573 0.80 PDK2 (0.37) EP300PDK2PARP1CA1CA2
SCHEMBL12424649 0.79 KMT2A (0.33) EP300PDK2PARP1TSHRGAA
SCHEMBL12424598 0.79 CNR2 (0.35) EP300PDK2PARP1TP53GAA
SCHEMBL13868699 0.79 NPC1 (0.37) PDK2TSHRHPGDKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7976739-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2011-07-12 US disclosed
US-7976739-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2011-07-12 US disclosed
US-20100230649-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2010-09-16 US disclosed
US-20100230649-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100230649-A1 CHROMENE COMPOUND CCNT1, RB1, H1-0 ESR1 84/4885ESR2 233/4885EP300 1803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.